Citigroup
ATHE

Citigroup’s Alterity Therapeutics ATHE Stock Holding History

Citigroup’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1
Closed -$3 – 5942
2025
Q4 		$3 Sell
1
-635
-100% -$2.43K ﹤0.01% 5895
2025
Q3 		$2.4K Buy
+636
New +$3.07K ﹤0.01% 5438
2016
Q1 		– Sell
-3
Closed – – 7443
2015
Q4 		$0 Buy
+3
New +$153 ﹤0.01% 7536
2015
Q3 		– Sell
-12
Closed -$1K – 7362
2015
Q2 		$1K Buy
+12
New +$901 ﹤0.01% 7266
2015
Q1 		– Sell
-1
Closed – – 7190
2014
Q4 		$0 Sell
1
-28
-97% -$3.03K ﹤0.01% 7101
2014
Q3 		$4K Sell
29
-10
-26% -$1.34K ﹤0.01% 6625
2014
Q2 		$5K Buy
39
+14
+56% +$1.6K ﹤0.01% 6444
2014
Q1 		$4K Sell
25
-25
-50% -$13.8K ﹤0.01% 6635
2013
Q4 		$21K Buy
+50
New +$15K ﹤0.01% 6147

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Citigroup's ATHE Position: Q1 2026 in Review

Citigroup sold out of Alterity Therapeutics (ATHE) in Q1 2026, closing a stake of 1 share — an estimated $3 sold.

Citigroup first reported a position in ATHE in Q4 2013 and held it in 9 quarters. The position peaked at $21K in Q4 2013. 15 funds tracked by Wall St. Rank hold ATHE as of Q1 2026.

  • Citigroup reported no remaining Alterity Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 1 Alterity Therapeutics share in Q1 2026, an estimated $3.
  • Citigroup first reported a position in Alterity Therapeutics in Q4 2013 and held it in 9 quarters.
  • Citigroup's Alterity Therapeutics position peaked at $21K in Q4 2013.
  • 15 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.